- Sunday
- Monday
- Tuesday
- Wednesday
- Opening Ceremonies and Invocation
- John J. Conley Lecture: A Global Picture of the Tobacco Epidemic
Carolyn Dresler, MD
- Panel: Skull Base, Imaging, Image Guided and Endoscopic Approaches
Moderator: Patrick J. Gullane, MD
Current Concepts in the Diagnosis and Management of Anterior Skull Base Neoplasm: Giulio Cantu, MD
Skull Base Surgery: Open vs. Endoscopic - How Do We Decide?: Piero Nicolai, MD
Anterior Skull Base Reconstruction After Oncological Resections: A Comprehensive Algorithm: Dan M. Fliss, MD
Complications of Skull Base Surgery: How to Avoid Them?: Franco DeMonte, MD
- Panel: Cancer Prevention – Behavior
Moderator: Ellen R. Gritz
Treating Nicotine Dependence in the Oncologic Context: Robert A. Schnoll, PhD
Preventing and Managing Acute Psychosocial Distress Arising from Body Image Disturbance: Michelle C. Fingeret, PhD
The Interrelationship of Health Behaviors and Outcomes Among Head and Neck Cancer Patients: Sonia A. Duffy, PhD
Public Awareness Programs Related to Head and Neck Cancer: Terry A. Day, MD
- AHNS PRESIDENTIAL ADDRESS: "TAILORED TREATMENT, TEAMWORK, TRADEOFFS AND TRADITION:
HEAD AND NECK SURGICAL ONCOLOGY IN THE GENOMIC ERA"
Gregory T. Wolf, MD, University of Michigan Hospitals, Ann Arbor, Michigan, USA Introduction by Wayne M. Koch, MD
AHNS ACKNOWLEDGES UNRESTRICTED EDUCATIONAL GRANTS FROM OUR PLATINUM LEVEL DONORS
- BRUSTOL-MEYERS SQUIBB
- IMCLONE SYSTEMS
- MERCK KgaA
- SANOFI-AVENTIS
- AHNS RESEARCH AWARDS
- AHNS Alando J. Ballantyne Resident Research Pilot Grant
- AHNS Pilot Grants
- AHNS/AAO-HNSF Young Investigator Awards
- 2006 AHNS-ACS Career Development Award Presentation: Stephen Y. Lai, MD, PhD,
"Tumor Microenvironment Regulation of HIF-1 in Head and Neck Squamous Cell Carcinoma"
- KEYNOTE ADDRESS: "TARGETING SIGNALING PATHWAYS IN HEAD AND NECK CANCER"
Jennifer R. Grandis, MD, Eye and Ear Institute, Pittsburgh, Pennsylvania, USA
Introduction by Christine G. Gourin, MD
AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM SANOFI-AVENTIS
- CHRISTOPHER O’BRIEN LECTURE: "MANAGEMENT OF MALIGNANT MELANOMA"
Donald L. Morton, MD, John Wayne Cancer Institute, Santa Monica, California, USA
Introduction by Erich M. Sturgis, MD, MPH
- TARGETED THERAPIES IN HEAD AND NECK ONCOLOGY
Panel Moderator: Ezra Cohen, MD
Angiogenesis and Vascular Targeting - Jean-Louis Bourhis, MD, PhD
Radiation Interactions with EGFR and IGFR - Paul M. Harari, MD
mTOR Inhibitors: Is There a Role in HNSCC? - Cherie-Ann O. Nathan, MD
PKC in Head and Neck Cancer - Ezra Cohen, MD
-The panel will address novel targets in head and neck cancer (HNC) that are currently being investigated as therapeutics. At the conclusion of the panel, the participants will be able to:
- Understand the difference, rationale, and efficacy of angiogenic and vascular targeting in HNC.
- Understand the mechanism of radiosensitization of receptor tyrosine kinases directed against EGFR and IGFR.
- Understand the prognostic role of the mTOR pathway in HNC and the application of mTOR inhibitors in this disease.
- Define the PKC family of kinases and understand their relevance to HNC.
AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM BRISTOL MEYERS SQUIBB AND IMCLONE SYSTEMS
- JATIN P. SHAH SYMPOSIUM ON CLINICAL CONTROVERSIES IN HEAD & NECK SURGERY: THE ROLE OF THE SURGEON IN MULTIDISCIPLINARY CARE OF HEAD & NECK CANCER
Panel Moderator: John A. Ridge, MD, PhD
Oral Cavity and Oropharynx Cancer: Treatment Selection - Patrick J. Gullane, MD
Larynx and Hypopharynx Cancer: Treatment Selection - Jonas T. Johnson, MD
Morbidity and Complications of Head & Neck Radiation: When I Need a Surgeon - Parvesh Kumar, MD
At the completion of this panel, participants should be able to identify and to discuss:
- Clinical settings where either surgical or radiotherapeutic management may be employed with comparable results for cancers of the oral cavity and oropharynx.
- Clinical settings where either surgical or radiotherapeutic management may be employed with comparable results for cancers of the larynx and hypopharynx.
- Clinical settings where either surgery or radiation are preferred (due to oncologic or functional considerations) for cancers of the oral cavity and oropharynx.
- Clinical settings where either surgery or radiation are preferred (due to oncologic or functional considerations) for cancers of the larynx or hypopharynx.
- Limitations of radiation treatment for head and neck cancer.
- Management of stricture, radionecrosis, and post-radiation laryngeal dysfunction.
- TREATMENT OF LOCALLY ADVANCED CANCERS
Panel Moderator: David J. Adelstein, MD
Nonoperative, Multi-modality, Organ-preserving Treatment in Locally Advanced Larynx and Hypopharynx Cancer - Jean-Louis Lefebvre, MD
Current Multi-modality Treatments for Oropharynx Cancer - Volker G. Budach, MD, PhD
Nonoperative, Organ-preserving Treatment for Locally Advanced Disease - David E. Schuller, MD
Clinical and Laboratory Markers of Those Most Likely to Benefit from Nonoperative, Multi-modality Organ Preserving Treatment - Frank Worden, MD
Clinical and Laboratory Markers of Those Most Likely to Benefit from Nonoperative, Multi-Modality Organ Preserving Treatment - Thomas E. Carey, PhD
At the conclusion of the panel, participants will be able to:
- Summarize the current evidence and indications for nonoperative, multi-modality, organ-preserving treatment in locally advanced larynx and hypopharynx cancer.
- Discuss the limitations and the necessary precautions required in the choice of a nonoperative, organpreserving treatment for locally advanced disease.
- Summarize the current evidence and indications for nonoperative, multimodality treatment of oropharynx cancer, including the role of and indications for postoperative adjuvant therapy.
- Distinguish the clinical and laboratory markers of potential utility in identifying those most likely to benefit from nonoperative, multimodality organ preserving treatment.
AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM SANOFI-AVENTIS
- GENETICS/EPIGENETICS IN HEAD & NECK CANCERS
Panel Moderator: Wayne M. Koch, MD
Identification of Novel Gene Alterations in HNSCC - Bhuvanesh Singh, MD, PhD
Signal and Transcriptional Regulation of Gene Expression and Malignant Phenotype in HNSCC - Carter van Waes, MD, PhD
Methylation as a Tumor-specific Epigenetic Mechanism for Development of HNSCC - Andre L. Carvalho, MD, PhD
Paraganglioma and Pheochromocytoma: Genetics Relevant for Surgeons - Patrick Ha, MD
At the conclusion of the panel, the participants will be able to:
- Understand how alterations affecting several key signal activated transcription factors impact gene expression and the malignant phenotype, and implications for molecular therapy of HNSCC.
- Be familiar with methods being employed to search for and validate the identity of novel genes involved in HNSCC pathogenesis.
- Be familiar with alternate mechanisms for tumor-specific alterations in gene function (epigenetic changes) and how these contribute to the development of malignancy.
- Be aware of mutations in the SDH genes especially as they relate to head and neck paragangliomas, carotid body tumors and the need for surgeons to be aware of the hereditary nature of these as well as the possibility of associated functioning tumors.
- SYSTEMIC THERAPY FOR DISTANT METASTASES
Panel Moderator: Yungpo Bernard Su, MD
Current standards in the Treatment of Metastatic Squamous Head and Neck Cancer - Jennifer E. Tseng, MD
EGFR-Targeted Therapies: Emerging Data and Future Directions - Jan B. Vermorken, MD
VEGF and Emerging Targets for Treatment of Metastatic Squamous Head and Neck Cancer - Anthanassios E. Argiris, MD
This panel will address topics relating to the systemic treatment of distant metstatic disease from squamous cell carcinoma of the head and neck (SCCHN), with an emphasis on recent randomized data, as well as current
clinical trial therapies and related issues.
At the conclusion of the panel, the participants will be able to:
- Identify and understand the current data guiding standard-of-care systemic treatment for recurrent and/or metastatic SCCHN in the first line setting.
- Identify and understand the current data guiding standard-of-care systemic treatment for recurrent and/or metastatic SCCHN in the salvage setting.
- Understand selected current strategies and ongoing clinical trial efforts in the development of new systemic
therapies for recurrent and/or metastatic SCCHN.
- CARCINOMA OF THE ORAL TONGUE
Panel Moderator: Anil K. D’Cruz, MD
Surgical Management, Reconstruction and Quality of Life Issues After Resection - Snehal Patel, MD
Radiotherapy and Postoperative Adjuvant Treatments in Early Tongue Cancers - Vincent Grégoire, MD, PhD
Role of Chemo in Multidisciplinary Care - Bonnie S. Glisson, MD
Reconstruction of the Oral Tongue- Surgical Techniques - Uttam K. Sinha, MD
At the conclusion of this panel, participants will be able to:
- Understand the global incidence of tongue cancers.
- Understand the role of the work up, MRI and intraoral ultrasound measurement of tumor thickness in tongue cancers.
- Identify brachytherapy/external beam and postoperative adjuvant treatments.
- Understand the role of organ preservation, as induction, in palliation and chemoprevention in carcinomas of the tongue.
- Understand when to reconstruct the oral tongue, surgical techniques and QOL issues
- KEYNOTE LECTURE: "RADIATION THERAPY"
Jens Overgaard, MD, Aarhus University Hospital, Aarhus, Denmark
Introduction by Paul M. Harari, MD
- XRT AND TARGETED THERAPY
Panel Moderator: James A. Bonner, MD
Introduction to Radiotherapy with Targeted Agents - James A. Bonner, MD
Optimizing Combinations of Radiation with Cetuximab and Other Agents - Kie-Kian Ang, MD, PhD
The Future Implications of Hypoxia in the Treatment of Head and Neck Cancer - Jean Bourhis, MD, PhD
Targeted Therapies and Radiation: What Lies Beyond EGFR Inhibition? - David Raben, MD
The Role of Surgery in Patients Treated with Organ-Preservation Strategies - Eben L. Rosenthal, MD
At the conclusion of this panel, participants will be able to:
- Understand the multidisciplinary approach to locoregionally advanced head and neck cancer.
- Identify promising new targeted therapies in head and neck cancer.
- Appreciate how targeted therapies may enhance the effects of radiation or chemotherapy.
- Understand the complex role of surgery when organ preservation is the initial intent.
AHNS ACKNOWLEDGES AN UNRESTRICTED EDUCATIONAL GRANT FROM BRISTOL MEYERS SQUIBB AND IMCLONE SYSTEMS
- OROPHARYNX
Panel Moderator: David I. Rosenthal, MD
Surgery: Indications and New Technology - Young-Ik Son, MD, PhD
Understand the Rationale and Current Role of Induction Chemotherapy - David G. Pfister, MD
HPV: Prognosis, Prevention, Treatment Selection - Frank Worden, MD
Functional MR: Assessing Treatment Response - Laurie A. Loevner, MD
Concurrent Chemoradiation for Stage III/IV: Initial or after induction - David I. Rosenthal, MD
This panel will address topics relating to oropharynx cancer, with an emphasis on treatment selection options and how they are affected by evolving developments in causation and the therapeutic and diagnostic modalities. The speakers are listed along with panel objectives related to the presentations.
At the conclusion of the panel, the participants will be able to:
- Understand the still current indications for surgery in oropharynx cancer that has evolved in the last decade to a predominantly non-surgical disease.
- Understand the indications, contraindications, rationale, and options for induction chemotherapy.
- Understand the evolving role of HPV in causation, prevention, and affect on selection of treatment and treatment intensity for HPV+ tumors.
- Understand new and emerging MR imaging techniques to assess response to therapy.
- Understand indications and contra-indications for concurrent chemoradiation, and how induction chemotherapy affects drug/treatment selection.
- EARLY LARYNGEAL CANCER
Panel Moderator: Brian O’Sullivan, MD
Introduction and Disease Description and Management Approaches - Brian O’Sullivan, MD
Management Using Radiotherapy - Sandro V. Porceddu, MD
Management by Endoscopic Surgical Techniques - Petra Ambrosch, MD, PhD
Management by Conservation Partial Laryngectomy - William B. Coman, MD
Voice Rehabilitation and Voice Outcome - Kwang Hyun Kim, MD, PhD
This panel will address the management of early stage squamous cell carcinoma (SCC) of the glottic and supraglottic larynx. It will address the following issues in relation to the diagnosis, evaluation and treatment of T1-2N0 SCC in these anatomic sites.
At the conclusion of this panel, participants will have an enhanced knowledge about the management of early
larynx cancer and be able to:
- Identify and clinically evaluate a patient with early stage laryngeal cancer.
- Determine the appropriate use of imaging investigations.
- Present a balanced view of the options for management.
- Discuss target volumes, planning techniques and dose fractionation approaches for radiotherapy.
- Describe the role of laser treatment in early laryngeal cancer.
- Understand conservation partial laryngectomy techniques and the clinical situations guiding their choice.
- Appreciate the indications for and the techniques employed for management of the ‘at risk’ neck.
- Know the indications for adjuvant radiotherapy following surgical management.
- Have awareness of a potential emerging role for chemotherapy in early laryngeal cancer.
- Be aware of results of voice rehabilitation and speech therapy.
- KEYNOTE LECTURE: "EPIGENETICS AND ORAL CANCER"
Richard Shaw, MD, FRCS, FDS, University of Liverpool, Liverpool, England, United Kingdom
Introduction by Eduardo Mendez, MD
- MILTON J. DANCE, JR. LECTURE: "EVALUATION AND MANAGEMENT OF THE N0 NECK"
C. René Leemans, MD, PhD, VU Medical Center, Amsterdam, The Netherlands
Introduction by Andre L. Carvalho, MD, PhD
- NECK DISEASE - MULTIDISCIPLINARY
Panel Moderator: Randall P. Morton, MD
Introduction: Does it Matter Who Performs Surgery for Cervical Node Metastases? - Randall P. Morton, MD
Identifying the “At-Risk” N0 Neck: When and How to Treat - Luiz P. Kowalski, MD, PhD
Management of the Contralateral Neck: Observation, Radiotherapy or Surgery? - Greg Krempl, MD
PET-CT Scans: Role in RT Planning and Surveillance - June Corry, MD
Surgical Salvage of the Irradiated Neck - Paul M. Spring, MD, MS
At the conclusion of the panel, participants will be able to:
- Appreciate factors that determine the need for treatment of a N0 neck.
- Understand the role of PET-CT scanning in patients with advanced metastatic neck disease.
- Be familiar with the issues relating to surgery in the irradiated neck.
- SALIVARY CANCERS
Panel Moderator: Kerry D. Olsen, MD
Changing Patterns of Surgical Care for Salivary Cancer - Eugene N. Myers, MD
Pathology and Molecular Biomarkers in the Assessment of Salivary Gland Cancer - Adel El-Naggar, MD, PhD
Treatment of Radiated Salivary Glands, Bottled Water to Tissue Engineering - Robert L. Witt, MD
Radiation for Salivary Cancers - Adam S. Garden, MD
Medical Treatment for Salivary Gland Cancer - Lisa Licitra, MD
At the conclusion of the panel, participants will be able to:
- Determine how the surgical management of salivary gland cancers changing.
- Determine when radiation therapy should be used to treat salivary gland malignancies.
- Determine what is the value of adding chemotherapy, hormonal or targeted therapy to the management of
salivary gland cancer.
